Emma-Anne Karlsen is researching ways to enhance the effectiveness of monoclonal antibodies (mAb) in cancer treatment, addressing the issue of low response rates (below 35%) in certain cancers, costing Australia an estimated $355 million annually for non-responders. Her solution involves repurposing prochlorperazine (PCZ), a low-cost hospital medication, to transform non-responders into responders.
Falling Walls
Falling Walls Science Summit 2023
Login or Register
You need to be logged in to use this feature.
Breaking the Wall of Cancer Therapy Resistance
Emma-Anne Karlsen is a general surgery registrar and PhD Candidate at the University of Queensland’s Frazer Institute, where she investigates novel breast cancer biomarkers and therapeutic strategies. She hopes to build a career as a surgeon-scientist in order to improve global health outcomes for women with breast cancer.
Further Activities to have a look at